Recent news highlights Globus Medical's Q3 earnings surpassing expectations, reflecting ongoing operational performance.

• Globus Medical reported Q3 earnings that exceeded expectations, indicating continued operational strength [N1].

The company benefits from a strong regulatory compliance framework and a diversified product portfolio including regenerative biologics and medical devices cleared by the FDA. Its strong liquidity position and profitability as of Q3 2026 support operational stability. Continued innovation and regulatory approvals could enhance its market position. Positive recent earnings news suggests ongoing operational execution.

Risks include potential regulatory enforcement actions due to non-compliance with FDA or international standards, which could lead to fines, recalls, or restrictions impacting sales and reputation. Dependence on a limited number of tissue suppliers poses supply chain risks. Negative publicity related to tissue sourcing or product safety could reduce demand. Healthcare fraud and abuse laws impose compliance risks that could result in penalties or operational disruptions.

Globus Medical's moat is supported by its regulatory clearances and approvals, which create barriers to entry for competitors. Its specialized regenerative biologics products require complex sourcing of human tissue and compliance with stringent FDA and international regulations, limiting competition. The company's established relationships with suppliers and distributors, along with its compliance infrastructure, contribute to its competitive position. However, dependence on a limited number of tissue suppliers and regulatory risks remain potential vulnerabilities.

• Regulatory Compliance Risk: Failure to comply with FDA and international regulations could result in enforcement actions including fines, recalls, injunctions, and criminal penalties, adversely affecting business and reputation [S1].
• Supply Chain Risk: Dependence on a limited number of third-party suppliers for human tissue creates risks related to availability, pricing, quality, and delivery, which could disrupt manufacturing [S1].
• Negative Publicity Risk: Media reports or allegations concerning improper tissue recovery or disease transmission could reduce demand for regenerative biologics and impact tissue supply [S1].
• Healthcare Fraud and Abuse Risk: The company is subject to complex U.S. federal and state laws regarding healthcare fraud and abuse, including anti-kickback statutes and false claims laws, which could lead to penalties or exclusion from government programs [S1].

• Globus Medical Inc is a medical device company subject to extensive U.S. FDA and international regulatory requirements, including 510(k) clearances, PMAs, and compliance with quality management systems and good tissue practices as applicable [S1].
• The company markets human tissue products classified as Section 361 HCT/Ps, which are not subject to FDA premarket clearance but are regulated for donor eligibility, screening, labeling, and post-market reporting [S1].
• Failure to comply with FDA or international regulations can lead to enforcement actions such as warning letters, fines, recalls, injunctions, and criminal penalties, which could materially affect the company's business and reputation [S1].
• Globus Medical depends on a limited number of third-party suppliers for human tissue used in regenerative biologics products, with risks related to supply availability, pricing, quality, and delivery schedules [S1].
• Negative publicity regarding tissue recovery methods or disease transmission could reduce demand for regenerative biologics products and impact tissue supply [S1].
• The company is subject to U.S. healthcare fraud and abuse laws, including anti-kickback statutes and false claims laws, which affect its relationships with healthcare providers and distributors [S1].
• As of September 30, 2026, Globus Medical reported cash and equivalents of $441.3 million, current assets of $2.18 billion, current liabilities of $508 million, and a current ratio of 4.3, indicating strong liquidity [S2].
• For the nine months ended September 30, 2026, the company reported revenue of $763.7 million and net income of $141.2 million, with basic EPS of $1.05 and diluted EPS of $1.04 [S2].
• Recent news highlights include Globus Medical's Q3 earnings surpassing expectations, indicating ongoing operational performance updates [N1].